Form 4/A for SYRE Spyre Therapeutics, Inc.
Accepted 2023-12-08 00:00:00 ET · period of report 2023-11-22 · accession 0000950170-23-069048 · SEC index · Original document
Summary rows
Aggregated the way they appear in lists: one row per insider, transaction code and security table.
| X | Filed | Traded | Ticker | Insider | Title | Type | Price | Qty | Owned | ΔOwn | Value |
|---|---|---|---|---|---|---|---|---|---|---|---|
| DAI | 2023-12-08 | 2023-11-24 | SYRE | Albers Jeffrey W. | Dir | C - Cnv Deriv | $0.00 | +34.4K | 34.4K | New | $0 |
| DAI | 2023-12-08 | 2023-11-24 | SYRE | Albers Jeffrey W. | Dir | C - Cnv Deriv | $0.00 | -859 | 0 | -100% | $0 |
| DA | 2023-12-08 | 2023-11-22 | SYRE | Albers Jeffrey W. | Dir | A - Grant | $0.00 | +50.0K | 50.0K | New | $0 |
Purchase Sale Sale after option exercise All abbreviations
Every reported transaction
| # | Table | Security | Date | Code | A/D | Shares | Price | Owned after | Own | Exercise / expiry | Underlying | Footnotes |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 1 | Common | Common Stock | 2023-11-24 | C | A | 34,360 | $0.00 | 34,360 | I By Sessions LLC | — | — | |
| 2 | Derivative | Series A Preferred Stock | 2023-11-24 | C | D | 859 | $0.00 | 0 | I | — · — to — | 34,360 Common Stock | (F1) Following stockholder approval of the conversion of Series A Preferred Stock into shares of Common Stock, each share of Series A Preferred Stock automatically converted on November 24, 2023 into 40 shares of Common Stock, subject to certain limitations. |
| 3 | Derivative | Stock Option (Right to Buy) | 2023-11-22 | A | A | 50,000 | $0.00 | 50,000 | D By Sessions LLC | $10.39 · — to 2033-11-22 | 50,000 Common Stock | (F2) This option represents a right to purchase 50,000 shares of the Issuer's Common Stock, which will vest and become exercisable in 36 equal monthly installments beginning on November 22, 2023 until such time as the option is 100% vested, subject to the Reporting Person's continuous service with the Issuer at each vesting date. |